arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Trevi Therapeutics, Inc.

TRVI

$12.80 ▼ -1.19 (-8.51%) at close

9 Visible periods

20 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Neutral

auto_awesome

Analytical Summary

Trevi Therapeutics, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $1.7B

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -26.9% ↗

FCF / Share $-0.31 ↗

Trailing P/E —

Price / Book 9.0x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

9-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-42.76M

↑ +10.8% —

FCF / Share Free cash flow per share

$-0.31

↑ +16.8% —

Health Breakdown

Returns ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
EPS Growth YoY (%)	31.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-62.1% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	35.6% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	69.8% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	10.8% Fair ↑ Fair Improving Year-over-year change in net income	-64.8% Weak ↓ Weak Declining Year-over-year change in net income	0.3% Caution ↑ Caution Improving Year-over-year change in net income	14.1% Fair ↑ Fair Improving Year-over-year change in net income	-3.6% Weak ↑ Weak Improving Year-over-year change in net income	-25.8% Weak Weak Year-over-year change in net income	-26.8% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	16.8% Good ↓ Good Declining Year-over-year change in free cash flow	-16.8% Weak ↓ Weak Declining Year-over-year change in free cash flow	26.7% Excellent Excellent Year-over-year change in free cash flow	65.4% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Effective Tax Rate (%) (%)	0.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.6% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
FCF / Net Income (x)	0.98x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.10x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.97x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Return on Invested Capital (%)	-26.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-51.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-41.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-27.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-190.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-119.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-48.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	16.7% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-25.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-46.5% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-37.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-24.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-84.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-68.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-44.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-174.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-23.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-256%)	-48.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-421%)	-35.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-335%)	-27.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-281%)	-198.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1425%)	-120.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-900%)	-47.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-418%)	18.8% Good Good Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+25%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Interest Coverage (x)	—	-12881.00x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-86.76x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-25.72x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-27.02x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-71.25x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	-105.79x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-18.91M	$-34.10M	$-32.40M	$-12.59M	$-36.83M	$-45.00M	$-57.31M	$-7.20M	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Basic EPS, GAAP (USD)	$-0.32	$-0.47	$-0.29	$-0.45	$-1.49	—	—	—	—
Free Cash Flow per Share (USD)	$-0.31	$-0.38	$-0.32	$-0.44	$-1.27	—	—	—	—
Book Value per Share (USD)	$1.43	$1.06	$1.21	$1.79	$0.60	$1.47	$3.06	$-249.64	—
Tangible Book Value per Share (USD)	$1.43	$1.06	$1.21	$1.79	$0.60	$1.47	$3.06	$-249.64	—
Basic Weighted Avg Shares (shares)	134.75M	101.97M	99.03M	64.54M	22.84M	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Working Capital (USD)	$181.91M	$98.92M	$81.72M	$109.22M	$25.23M	$40.71M	$54.35M	$6.15M	—
Total Equity (USD)	$183.24M	$99.64M	$82.55M	$107.46M	$17.07M	$27.28M	$54.55M	$-109.49M	$-84.43M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗
Depreciation Expense (USD)	$144.00K	$147.00K	$123.00K	$43.00K	$50.00K	$47.00K	$39.00K	$23.00K	—
Net Income, GAAP (USD)	$-42.76M	$-47.91M	$-29.07M	$-29.15M	$-33.94M	$-32.76M	$-26.05M	$-20.55M	—
Operating Cash Flow (USD)	$-42.09M	$-38.26M	$-31.71M	$-28.18M	$-28.95M	$-29.00M	$-23.09M	$-18.29M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 9 years · 35 quarters

Trevi Therapeutics, Inc.

Analytical Summary

9-Year Financial Trajectory

Health Breakdown

Statement lens

Benchmark Lens

Percentile Rankings

Peer Comparison

Compare TRVI with peers